Top 3 Healthcare Stocks for February 2023

Here are 3 companies under heavy accumulation.

Regeneron Pharmaceuticals, Inc. (REGN) Analysis

First is biotech firm Regeneron Pharmaceuticals (REGN). The healthcare stock is up 8% in 2023.

Healthy institutional accumulation has likely helped lift the shares higher, which you can see via the MAPsignals chart below. Since September there’ve been 6 unusually large volume inflows (green bars):


With a 12-month forward P/E of 18.5, shares could be attractive after a pullback. According to FactSet, the company is estimated to earn $46.01 per share in fiscal year 2024.

One thing is for sure, the shares have been in demand lately.

Stryker Corp. (SYK) Analysis

Next up is Stryker Corp. (SYK) which is a medical technology company operating in orthopaedics & spine segments (and more). At MAPsignals, we believe in following large institutional flows. With the stock gaining 15% in 2023, we believe healthy accumulation is part of the story.

Since late November there’ve been 10 days where the stock jumped in price alongside outsized volumes. That can mean there’s institutional interest:


The 12-month forward P/E is pegged at 27.9X according to FactSet. Also, the company is expected to earn $11.13 per share in fiscal year 2024.

This unusual trading action suggests investors are expecting upside for the company in 2023.

Vertex Pharmaceuticals Inc. (VRTX) Analysis

The number 3 healthcare firm rising this year is Vertex Pharma (VRTX). This biotech company engages in the development and manufacturing of drugs for patients with serious diseases. The market cap is just over $77 billion.

The stock has dropped recently but gained 4% in 2023. Notably, the shares have seen 3 large accumulation signals since October:


This has been one of the highest ranked stocks in our research for years.

Strong sector leadership could mean there’s more upside for the group in 2023.

Bottom Line

REGN, SYK, & VRTX represent 3 of the top healthcare stocks so far in February 2023. Healthy institutional accumulation signals make these stocks worthy of extra attention.

To learn more about MAPsignals’ institutional process please visit:

Disclosure: As of the time of this writing, the author holds no positions in REGN, SYK, or VRTX at the time of this writing.

This article was originally posted on FX Empire